Table 4. Effect of female availability treatment on sperm quality traits in the guppy.
Multivariate | Univariate | |||||||||
Source | Df | Pillai | P | Sperm trait | Estimate | df | SS | F | P | Effect size |
Treatment | 1, 5, 59 | 0.051 | 0.680 | Viability | –0.015 (–0.110, 0.080) | 1 | 0.0001 | 0.003 | 0.960 | –0.08 (–0.58, 0.42) |
Velocity | 4.479 (–2.631, 11.59) | 1 | 321.5 | 1.546 | 0.218 | 0.32 (–0.18, 0.82) | ||||
Sperm head | 0.017 (–0.029, 0.062) | 1 | 0.005 | 0.641 | 0.427 | 0.18 (–0.31, 0.68) | ||||
Sperm midpiece | –0.176 (–0.642, 0.291) | 1 | 0.273 | 0.304 | 0.583 | –0.19 (–0.69, 0.31) | ||||
Sperm flagellum | 0.367 (–0.243, 0.977) | 1 | 1.504 | 0.983 | 0.325 | 0.30 (–0.20, 0.80) | ||||
Male size | 1, 5, 59 | 0.184 | 0.031 | Viability | 0.066 (0.010, 0.122) | 1 | 0.294 | 7.886 | 0.007 | 0.59 (0.09, 1.10) |
Velocity | 1.661 (–2.540, 5.862) | 1 | 94.20 | 0.453 | 0.503 | 0.20 (–0.30, 0.70) | ||||
Sperm head | 0.006 (–0.021, 0.033) | 1 | 0.002 | 0.267 | 0.607 | 0.11 (–0.39, 0.61) | ||||
Sperm midpiece | 0.164 (–0.112, 0.440) | 1 | 1.889 | 2.107 | 0.152 | 0.30 (–0.20, 0.80) | ||||
Sperm flagellum | 0.051 (–0.309, 0.412) | 1 | 0.029 | 0.019 | 0.891 | 0.07 (–0.42, 0.57) | ||||
Iridescence | 1, 5, 59 | 0.103 | 0.254 | Viability | 0.693 (–0.014, 1.401) | 1 | 0.143 | 3.836 | 0.055 | 0.50 (–0.01, 1.00) |
Velocity | –17.015 (–69.84, 35.81) | 1 | 86.10 | 0.414 | 0.522 | –0.16 (–0.66, 0.33) | ||||
Sperm head | 0.057 (–0.280, 0.393) | 1 | 0.0001 | 0.113 | 0.738 | 0.09 (–0.41, 0.58) | ||||
Sperm midpiece | 1.976 (–1.493, 5.445) | 1 | 1.162 | 1.296 | 0.259 | 0.29 (–0.21, 0.79) | ||||
Sperm flagellum | –4.674 (–9.204, –0.144) | 1 | 6.500 | 4.251 | 0.043 | –0.52 (–1.03, –0.02) | ||||
Residual | Viability | 63 | 2.348 | |||||||
Velocity | 63 | 1310 | ||||||||
Sperm head | 63 | 0.531 | ||||||||
Sperm midpiece | 63 | 56.48 | ||||||||
Sperm flagellum | 63 | 96.33 |
Multivariate and univariate results are presented. Parameter estimates and effect sizes [59] are presented with 95% confidence intervals. Parameter estimates are relative to the high female availability (HFA) treatment level.